Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 759-765 , July 2008

Plasma Elevations of Tumor Necrosis Factor-Receptor-1 at Day 7 Postallogeneic Transplant Correlate with Graft-versus-Host Disease Severity and Overall Survival in Pediatric Patients

  • Carrie L. Kitko

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    • Corresponding Author InformationCorrespondence and reprint requests: Carrie Kitko, MD, Blood and Marrow Transplant Program, 5303 Cancer Center, 1500 E. Medical Center Drive, SPC 5941, Ann Arbor, MI 48109-5941.
    • ,
  • Sophie Paczesny

      Affiliations

    • Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    • ,
  • Gregory Yanik

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • Thomas Braun

      Affiliations

    • Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, Michigan
    • ,
  • Dawn Jones

      Affiliations

    • Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    • ,
  • Joel Whitfield

      Affiliations

    • Blood and Marrow Transplantation Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    • ,
  • Sung W. Choi

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • Raymond J. Hutchinson

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • James L.M. Ferrara

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan
    • ,
  • John E. Levine

      Affiliations

    • Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan
    • Department of Medicine, University of Michigan Medical School, Ann Arbor, Michigan

Received 29 November 2007 ,Accepted 9 April 2008.

References 

  1. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464–1472
  2. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant. 2002;8:387–394
  3. Wojnar J, Giebel S, Holowiecka-Goral A, et al. The incidence and risk factors for chronic graft-versus-host-disease. Ann Transplant. 2006;11:14–20
  4. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–5702
  5. Petersdorf EW. Immunogenomics of unrelated hematopoietic cell transplantation. Curr Opin Immunol. 2006;18:559–564
  6. Weisdorf DJ, McGlave PB, Ramsay NK, et al. Allogeneic bone marrow transplantation for acute leukaemia: comparative outcomes for adults and children. Br J Haematol. 1988;69:351–358
  7. McGlave PB, Haake R, Miller W, Kim T, Kersey J, Ramsay NK. Therapy of severe aplastic anemia in young adults and children with allogeneic bone marrow transplantation. Blood. 1987;70:1325–1330
  8. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. Blood. 2005;105:410–419
  9. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006;12:1277–1284
  10. Giebel S, Giorgiani G, Martinetti M, et al. Low incidence of severe acute graft-versus-host disease in children given haematopoietic stem cell transplantation from unrelated donors prospectively matched for HLA class I and II alleles with high-resolution molecular typing. Bone Marrow Transplant. 2003;31:987–993
  11. Sedlacek P, Formankova R, Keslova P, et al. Low mortality of children undergoing hematopoietic stem cell transplantation from 7 to 8/10 human leukocyte antigen allele-matched unrelated donors with the use of antithymocyte globulin. Bone Marrow Transplant. 2006;38:745–750
  12. Gassas A, Sung L, Saunders EF, Doyle JJ. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant. 2006;38:739–743
  13. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol. 2006;43:3–10
  14. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant. 1999;5:347–356
  15. Piguet PF, Grau GE, Allet B, Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987;166:1280–1289
  16. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95:2754–2759
  17. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90:3204–3213
  18. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–1891
  19. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992;10:411–452
  20. Schmaltz C, Alpdogan O, Muriglan SJ, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101:2440–2445
  21. Borsotti C, Franklin ARK, Lu SX, et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood. 2007;110:783–786
  22. Hill G, Teshima T, Gerbitz A, et al. Differential roles of IL-1 and TNF-α on graft-versus-host disease and graft versus leukemia. J Clin Invest. 1999;104:459–467
  23. Holler E, Kolb HJ, Mittermuller J, et al. Modulation of acute graft-versus-host-disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNF alpha) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF alpha (MAK 195F). Blood. 1995;86:890–899
  24. Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood. 1992;79:3362–3368
  25. Holler E, Kolb HJ, Moller A, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood. 1990;75:1011–1016
  26. Levine J, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute GVHD. Blood. 2008;111:2470–2475
  27. Busca AA, Locatelli FF, Marmont FF, Ceretto CC, Falda MM. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82:45–52
  28. Holler E, Kolb HJ, Hintermeier-Knabe R, et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc. 1993;25:1234–1236
  29. Hintermeier-Knabe R, Brockhaus M, Holler E, et al. Sequential release of tumor necrosis factor alpha and tumor necrosis factor receptors in complications of human bone marrow transplantation. In:  Freund M,  Link H,  Schmidt R,  Welte K editor. Cytokines in Hemopoiesis, Oncology, and AIDS II. Berlin: Springer-Verlag; 1992;p. 443–448
  30. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392–399
  31. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295–304
  32. Lee KH, Choi SJ, Lee JH, et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica. 2005;90:939–948
  33. Kebriaei P, Kline J, Stock W, et al. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant. 2005;35:965–970
  34. Song KW, Lipton JJ. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?. Bone Marrow Transplant. 2005;36:183–191
  35. Lee S, Cho B, Kim S, et al. Allogeneic stem cell transplantation in first complete remission enhances graft-vs.-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-vs.-host disease. Biol Blood Marrow Transplant. 2007;13:1083–1094
  36. Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11:108–114
  37. Al-Ali HK, Brand R, van Biezen A, et al. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Leukemia. 2007;21:1945–1951
  38. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106:1113–1122

PII: S1083-8791(08)00148-1

doi: 10.1016/j.bbmt.2008.04.002

Biology of Blood and Marrow Transplantation
Volume 14, Issue 7 , Pages 759-765 , July 2008

Article Tools

* Image Usage & Resolution